FIELD: medicine; biotechnology.
SUBSTANCE: group of inventions can be used to produce bone morphogenetic proteins. Disclosed is a polypeptide, which is a variant of bone morphogenetic protein 9 (BMP9), in which there is a signal transmission capacity in the endothelium and osteogenic activity is absent, wherein the amino acid sequence of said version of BMP9 differs from the amino acid sequence SEQ ID NO: 4 consists in presence of replacement selected from group consisting of F362A, D366A, I375A, L379A, S402A, D408A, Y416A and Y418A. Also disclosed is a vector for expression of said polypeptide.
EFFECT: use of inventions enables producing bone morphogenetic proteins capable of transmitting a signal to the endothelium and with osteogenic activity absent.
11 cl, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION | 2007 |
|
RU2559532C2 |
| NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS FOR TREATING DISEASES ASSOCIATED WITH MUSCULAR ATROPHY | 2016 |
|
RU2733492C2 |
| COMPOSITIONS AND METHODS OF PULMONARY HYPERTENSION TREATMENT | 2017 |
|
RU2748278C2 |
| RECOMBINANT PLASMID, RECOMBINANT STRAIN, RECOMBINANT PROTEIN BMP-7 AND EXTRACTION METHOD OF RECOMBINANT PROTEIN IN DIMERIC FORM | 2012 |
|
RU2499047C1 |
| RECOMBINANT PLASMID, RECOMBINANT STRAIN, RECOMBINANT PROTEIN BMP-2 AND EXTRACTION METHOD OF RECOMBINANT PROTEIN IN DIMERIC FORM | 2012 |
|
RU2499048C1 |
| NEW CORNEAL TREATMENT WITH LAMININ | 2015 |
|
RU2718062C2 |
| USING LAMININ IN CORNEAL ENDOTHELIAL CELL CULTURE | 2014 |
|
RU2704984C1 |
| MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
